Nonalcoholic Fatty Liver Disease Increases the Risk of Anxiety and Depression.
Journal
Hepatology communications
ISSN: 2471-254X
Titre abrégé: Hepatol Commun
Pays: United States
ID NLM: 101695860
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
received:
30
01
2020
revised:
16
04
2020
accepted:
07
05
2020
entrez:
14
9
2020
pubmed:
15
9
2020
medline:
15
9
2020
Statut:
epublish
Résumé
Nonalcoholic fatty liver disease (NAFLD), depression, and anxiety disorders are frequent diseases, and data on mutual influence are inconsistent. The aim of this study was to explore the incidence of depression and anxiety in a large primary care cohort in Germany and to study the impact of NAFLD over a 10-year time frame. Patients with NAFLD diagnosed between 2010 and 2015 were matched to a cohort without NAFLD controlling for age, sex, physician, index year, and Charlson comorbidity index. The primary outcome of the study was the incidence of depression, anxiety, and first prescription of antidepressant drugs. We compared 19,871 patients with NAFLD to 19,871 matched controls. Within 10 years of the index date, 21.2% of patients with NAFLD and 18.2% of controls were diagnosed with depression (
Identifiants
pubmed: 32923833
doi: 10.1002/hep4.1541
pii: HEP41541
pmc: PMC7471420
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1293-1301Informations de copyright
© 2020 The Authors. Hepatology Communications published by Wiley Periodicals LLC on behalf of American Association for the Study of Liver Diseases.
Références
J Hepatol. 2019 Mar;70(3):531-544
pubmed: 30414863
Aliment Pharmacol Ther. 2019 Sep;50(5):590-598
pubmed: 31328300
Int J Clin Pharmacol Ther. 2018 Oct;56(10):459-466
pubmed: 30168417
Gastroenterology. 2015 Mar;148(3):547-55
pubmed: 25461851
Gastroenterology. 2020 May;158(7):1929-1947.e6
pubmed: 32068022
Psychosom Med. 2006 Jul-Aug;68(4):563-9
pubmed: 16868265
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2013 May;56(5-6):786-94
pubmed: 23703499
J Psychosom Res. 2011 Nov;71(5):319-24
pubmed: 21999975
Endocr Rev. 2020 Jan 1;41(1):
pubmed: 31629366
BMC Med. 2019 Jul 4;17(1):123
pubmed: 31269936
Arch Gen Psychiatry. 2010 Mar;67(3):220-9
pubmed: 20194822
Front Mol Neurosci. 2017 May 08;10:134
pubmed: 28533742
Physiology (Bethesda). 2019 Mar 1;34(2):123-133
pubmed: 30724127
Int J Psychiatry Med. 2002;32(3):235-47
pubmed: 12489699
Lancet. 2016 Oct 8;388(10053):1545-1602
pubmed: 27733282
Lancet. 2019 Dec 14;394(10215):2184-2196
pubmed: 31813633
Clin Gastroenterol Hepatol. 2019 Sep;17(10):2085-2092.e1
pubmed: 30580090
Hepatology. 2019 Jun;69(6):2672-2682
pubmed: 30179269
Hepatol Commun. 2019 Sep 30;3(11):1472-1481
pubmed: 31701071
Nat Rev Gastroenterol Hepatol. 2018 Jan;15(1):11-20
pubmed: 28930295
J Hepatol. 2016 Jun;64(6):1388-402
pubmed: 27062661
J Affect Disord. 2016 Nov 15;205:393-399
pubmed: 27588358
J Nurs Scholarsh. 2017 Jul;49(4):389-399
pubmed: 28692781
Med Care. 2005 Nov;43(11):1130-9
pubmed: 16224307
J Gastroenterol Hepatol. 2015 Jun;30(6):1009-14
pubmed: 25619308
J Gastroenterol Hepatol. 2013 Aug;28 Suppl 1:68-76
pubmed: 23855299
Liver Int. 2013 Aug;33(7):1062-70
pubmed: 23560860
Int J Clin Pharmacol Ther. 2009 Oct;47(10):617-26
pubmed: 19825325
Aliment Pharmacol Ther. 2018 Nov;48(10):1109-1116
pubmed: 30288767
JAMA Neurol. 2018 Jan 1;75(1):97-104
pubmed: 29159396
J Hepatol. 2018 Oct;69(4):896-904
pubmed: 29886156
Psychosomatics. 2013 Jan-Feb;54(1):52-9
pubmed: 23295007
BMC Med. 2019 May 20;17(1):95
pubmed: 31104631
Diabetes Care. 2019 Jan;42(Suppl 1):S34-S45
pubmed: 30559230
J Clin Endocrinol Metab. 2004 Jan;89(1):266-71
pubmed: 14715860
Curr Opin Lipidol. 2011 Dec;22(6):479-88
pubmed: 22002020
Prog Neuropsychopharmacol Biol Psychiatry. 2004 May;28(3):435-51
pubmed: 15093950
Metab Brain Dis. 2011 Mar;26(1):29-35
pubmed: 21181433
J Affect Disord. 2012 Dec 1;141(1):72-8
pubmed: 22391518
Psychosomatics. 2011 Mar-Apr;52(2):127-32
pubmed: 21397104